Skip to main content
. 2021 Jul 13;5(6):794–803. doi: 10.1002/ags3.12489

TABLE 2.

Summary of response and treatment cycle of nivolumab treatment

Patients with measurable lesions n = 163 (%)
Complete response 6 (3.6)
Partial response 13 (8.0)
Stable disease 26 (16.0)
Progressive disease 115 (70.6)
Not evaluated 3 (1.8)
Overall response rate 19 (11.7)
Disease control rate 45 (27.6)
All patients n = 278 (%)
Disease control rate 75 (27.0)
Median treatment cycles (Interquartile range) 4 (3‐8)